47 results about "Peptide specificity" patented technology

The invention provides an infectious bronchitis virus antigen epitope fusion peptide, and the prepared antigen epitope fusion peptide can be used for preparing an antibody and can also be used as a coating antigen for preparing an indirect ELISA detection product. The amino acid sequence of the provided epitope fusion peptide is SEQ ID NO: 4. After antigen epitope analysis is performed on S1 protein of an infectious bronchitis virus strain through bioinformatics software, a plurality of antigen epitopes are fused to obtain the antigen epitope fusion peptide. Specificity tests show that the prepared antigen epitope fusion peptide is a coating antigen, does not have cross reaction with positive serum of other common pathogens, and only has good reaction with positive serum of GI-19 type IBV, that is, the antigen epitope fusion peptide has good serotype specificity as a detection antigen, and has small cross reaction with non-GI-19 type IBV antibody.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

To provide compositions and methods for increasing the stability of recombinant nanobodies. Also provided are recombinant Nanobodies comprising an IL-2 polypeptide that binds serum albumin, and uses thereof for treating cancer.SOLUTION: There is provided a recombinant Nanobody comprising a human serum albumin (HSA) binding polypeptide and an IL-2 polypeptide, wherein the HSA binding polypeptide specifically binds to an HSA epitope selected from the group consisting of epitope 1, epitope 2, epitope 3 and epitope 4.SELECTED DRAWING: Figure 16

This document relates to methods and materials involved in assessing and / or treating mammals having a caveolinopathy disease (e.g., immune-mediated rippling muscle disease (iRMD)). For example, methods and materials for detecting the presence of an autoantibody specific for a caveolae-associated protein 4 (cavin-4) polypeptide to identify a mammal as having iRMD as well as methods for treating a mammal identified having iRMD are provided. In some cases, cavin-4 polypeptides (and / or fragments thereof and / or variants thereof) can be used to detect the presence or absence of anti-cavin-4 polypeptide autoantibodies indicative of iRMD.

The invention relates to the technical field of biological medicine, in particular to a fibroblast-targeting phycocyanin conjugate, a sol preparation and application of the fibroblast-targeting phycocyanin conjugate, phycocyanin and targeting peptide are covalently linked through an SMCC cross-linking agent, LDL receptor-associated protein 1 highly expressed by fibroblast is specifically recognized through the targeting peptide, and efficient intracellular delivery is achieved; a water-soluble sol preparation carries phycocyanin to break through a cell barrier, and LRP1-rich fibroblasts in a wound are targeted and play a role in the fibroblasts. By inhibiting the EMT process of fiber cells, cell fibrosis and growth of wound bacteria are inhibited, scar formation is reduced, and wound healing is promoted. The defect that natural phycocyanin cells are poor in penetrability is overcome, scar-free healing is achieved by regulating Wnt5a / beta-catenin through targeted delivery, the effect is good, and application and popularization are convenient.

The present invention relates to a peptide binding to mesothelin, and use thereof, wherein the peptide of the present invention specifically binds to mesothelin and inhibits same, and thus the effect of inhibiting the migration and metastasis of cancer cells is exhibited. It has been identified that the peptide of the present invention was selected, using a phage peptide display technology, as one type of peptide that easily binds to cells in which human mesothelin is highly expressed, and thus the peptide binds to mesothelin and inhibits the migration of cancer cells. The peptide of the present invention is relatively stable in serum, and thus exhibits high potential as an anti-cancer therapeutic agent for inhibiting metastasis according to cancer progression and migration in the future, an anti-cancer drug delivery probe, and a cancer diagnostic probe.

The present invention relates to an antibody, an antigen-binding fragment thereof, or a peptide, which specifically binds to blood type antigen-specific immunoglobulins. The antibody, antigen-binding fragment thereof, and peptide according to the present invention have immunoglobulin inhibitory activity for preventing RBC aggregation. Accordingly, it is possible to effectively prevent or treat immune diseases that may occur during blood transfusion or organ transplantation between individuals having nonmatching blood types.

The invention relates to the technical field of biological medicine, in particular to application of AP3D1 as a drug action target in in-vitro screening of a blocking agent and a blocking peptide. Based on a regulation mechanism of a negative regulatory factor TGF-beta on transport and degradation of STING, the invention provides application of AP3D1 as a drug action target in in-vitro screening of a blocking agent, and two key regulation sites S9 and R26 of AP3D1 are obtained through screening. Meanwhile, corresponding blocking peptides are synthesized according to the two regulation and control sites, inactivation of an AP3D1-mediated tumor microenvironment factor on an STING signal is specifically prevented, closing of any one regulation and control site is achieved, and therefore transfer and degradation of STING are effectively limited. The blocking peptide can cooperate with various treatment modes such as chemotherapy, radiotherapy, PARP inhibitors and STING agonists, cGAS-STING signals in tumors in the treatment process are remarkably activated, and the more effective anti-tumor curative effect is achieved.

The present invention relates to adenoviral vectors and uses thereof wherein the viral capsid has been coated with a polypeptide capable of stimulating a peptide-specific immune response in an individual. Furthermore, the present invention relates to methods of treating diseases, such as cancer, by means of adenoviral vectors that have been coated with polypeptides capable of eliciting a peptide-specific immune response. The invention also relates to methods of coating adenoviral vectors by specific peptides and methods of identifying those peptides suitable for coating the capsid of an adenoviral vector.

The present invention relates to T cell receptors (TCRs), and in particular TCRs specific for peptides derived from melanoma associated antigen 4 (MAGE-A4). The invention also relates to antigen binding portions of said TCR, compositions comprising said TCR or portions, fusion proteins comprising said TCR or portions, nucleic acids and vectors encoding said TCR or portions, cells comprising said TCR or portions, and methods of treatment involving said TCR or portions.

The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

A multi-target DC vaccine based on tumor antigen epitope peptides and its application belong to the field of tumor immunotherapy technology. The vaccine comprises an hr-8 conjugate peptide, an immune adjuvant, a carrier, and an immune memory enhancer. The hr-8 conjugate peptide is a conjugate product formed by chemically linking an hr-8 targeting peptide with at least two different tumor antigen CTL epitope peptides. The immune adjuvant is a combined adjuvant system of the TLR9 agonist CpG ODN and the TLR3 agonist poly(I:C). The carrier is PLGA nanoparticles, and the immune memory enhancer is IL-7 and / or IL-15. This invention utilizes the specific binding of the hr-8 peptide to the DEC-205 receptor on the surface of dendritic cells to achieve efficient synergistic delivery and cross-presentation of multi-target antigens. The combined adjuvant and memory factor significantly enhance CTL activation and promote long-term immune memory formation, giving the multi-target DC vaccine advantages such as strong targeting, broad antigen coverage, and prolonged relapse-free survival.

The present invention belongs to the field of biomedicine technology, and specifically discloses an OBSCN new antigen epitope peptide and its application in the preparation of a drug for preventing and / or treating tumors. The amino acid sequence of the OBSCN new antigen epitope peptide provided by the present invention is shown in SEQ ID NO: 1-4, and the epitope peptide can effectively stimulate and induce the production of a mutant epitope peptide-specific CD8 with tumor killing function. + T lymphocytes specifically kill tumor cells that positively express new antigens. In addition, the patient coverage rate of the antigen epitopes contained in the epitope peptide is high, and it has good therapeutic potential and application prospects to make it into drugs (such as vaccines, cell preparations, etc.) for preventing and / or treating tumors. The drug provided by the present invention contains the OBSCN new antigen epitope peptide or its encoding nucleic acid, or a T cell antigen receptor or chimeric antigen receptor or its encoding nucleic acid that specifically recognizes the OBSCN new antigen epitope, and has a high clinical application value.

The present disclosure provides a prophylactic or therapeutic agent for a benign tumor. Provided is a prophylactic or therapeutic agent for a benign tumor, which comprises a WT1 peptide, an analog thereof, or a nucleic acid molecule encoding the same. In a specific embodiment, the present disclosure provides a prophylactic or therapeutic agent for a benign tumor, which comprises a WT1 peptide, an analog thereof, or a nucleic acid molecule encoding the same. In a preferred embodiment, the prophylactic or therapeutic agent for a benign tumor (e.g., familial adenomatous polyposis) according to the present disclosure comprises a killer-type and / or helper-type WT1 peptide. In a further preferred embodiment, the aforementioned WT1 peptide is a WT1 126 killer peptide and / or WT1 35 helper peptide. In another aspect, provided are WT1 peptide-specific CTLs, a method for inducing WT1-specific helper T cells, and a method for inducing dendritic cells presenting a WT1 peptide.

To provide methods and compositions for treating cancer such as breast cancer.SOLUTION: The presently disclosed subject matter relates to mutant PIK3CA-targeting TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity. The invention provides, for example, a T cell receptor (TCR) that specifically targets a PIK3CA peptide having H1047L mutation.SELECTED DRAWING: None

The application discloses autoimmune disease specific polypeptides, specific antibodies and application, and polypeptides are at least selected from one polypeptide in the following amino acid sequences: CarSP-1: VFLCPWRAEGGQCcarPSLLFDLRDETRNV; CarSP-2: FLCPWRAEGGQCcarPS; CarSP-3: AEGGQCcarPSLLFDLR; CarSP-4: CcarPSLLFDLRDETRNV and CarSP-5: VFLCPWRAEGGQCcarPSLLFDLRDCTRNV, cys4&cys23bridge; in view of the threat of autoimmune diseases to human health and life treatment, the application will have broad application prospects for the diagnosis and treatment of autoimmune diseases.

Antigen binding polypeptide specifically binding to a α / β T cell receptor (TCR) / cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector and / or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and / or treatment of a proliferative disease. Methods for improving or maintaining the binding and / or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the α / β TCR / CD3 complex.

A near-infrared imaging agent includes a targeting peptide that specifically binds to and / or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment, an optional spacer directly linked to the targeting peptide; and a near-infrared fluorophore that is directly or indirectly linked to the targeting peptide or optional spacer via a natural or non-natural linkage.

The present disclosure relates to multimers of a phosphatidylinositol-3 (GPC3)-specific peptide, a CD44-specific peptide, and an epithelial cell adhesion molecule (EpCAM)-specific peptide, and their use for the detection and treatment of epithelial cell-derived cancers, the epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and skin basal cell carcinoma. The present disclosure also relates to methods for monitoring the therapeutic response of a treated patient using the peptide multimers.

The invention provides a muscle-targeted adeno-associated virus capsid protein, an adeno-associated virus containing the muscle-targeted adeno-associated virus capsid protein, a vector and application. The present disclosure provides an adeno-associated virus capsid protein, which comprises a targeting peptide, and the targeting peptide comprises any one of the following amino acid sequences: SEQ ID NO: 1-19. According to the invention, a reasonable design and directed evolution combined method is adopted, and on the basis of a receptor integrin-RGD polypeptide specific binding principle, random amino acids are carried to adapt to construction and screening of the AAV vector of a capsid structure, so that the problems of poor stability of the capsid structure, change of histocompatibility and the like caused by direct insertion of a sequence are avoided; therefore, efficient transduction of muscular tissues is realized, and a reliable platform is provided for gene therapy.

The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and / or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1126 killer peptide and / or WT135 helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.

The invention belongs to the technical field of prevention and treatment of severely acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), and discloses an HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide, a polymer of the HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide and application of the HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide, and amino acid sequences of the HLA-E restrictive SARS-CoV-2 specific CD8 + T cell epitope peptide are shown as SEQ ID NO: 1-2. The HLA-E restricted CD8 < + > T cell epitope polypeptide provided by the invention can be applied to preparation of epitope peptide vaccines or induction of generation of epitope peptide specific CTL, so that the problem of low population coverage rate caused by HLA restriction of the existing vaccines is effectively solved, immune response coverage of wider crowds is realized through non-classical HLA-E molecules, and the HLA-E restricted CD8 < + > T cell epitope polypeptide can be applied to preparation of epitope peptide vaccines. The traditional Chinese medicine composition has the advantage of improving the universal immune response of people.

This invention discloses a biomarker for evaluating the immune status of COVID-19 vaccines and its application. The biomarker includes any one or a combination of at least two of the following SARS-CoV-2 viral peptides: M1, N16, N24, S15, S39, S44, S64, S82, S95, S104, or S115. This invention accurately identifies differences in peptide-specific antibody responses between asymptomatic and symptomatic patients. Through clustering heatmaps, it determines the differences in responses to peptides such as M1, N24, S15, S64, S82, S104, and S115 between vaccinated individuals and infected individuals. This effectively distinguishes between infected patients and vaccinated individuals, as well as between asymptomatic and symptomatic patients, providing a reference for COVID-19 treatment and peptide vaccine development.

The invention belongs to the field of biology, and discloses a calcitonin gene related peptide specific epitope peptide, an antigen, an antibody and a kit. The antigen epitope peptide is at least one of an antigen epitope peptide I with an amino acid sequence as shown in SEQ ID NO.1 and an antigen epitope peptide II with an amino acid sequence as shown in SEQ ID NO.2. An antibody obtained by immunizing an animal with an antigen obtained by using the antigen epitope peptide is used for qualitatively or quantitatively detecting the calcitonin gene-related peptide. The kit containing the antibody has good diagnostic sensitivity, specificity and repeatability, and can be used for preparing products for diagnosing migraine.

The application belongs to the technical field of biological medicine, and relates to a BCLAF1 protein Ser564 site phosphorylation antigen peptide, a specific antibody and a preparation method and application thereof. The application identifies BCLAF1 protein Ser564 as a key phosphorylation site through SIK2 kinase screening, and designs and synthesizes a phosphorylation antigen peptide based on the site. After immunizing animals, a polyclonal antibody specifically recognizing BCLAF1 Ser564 site phosphorylation modification is successfully prepared. The antibody has high sensitivity and strong specificity, is suitable for various detection platforms such as immunohistochemistry and immunoblotting, and can be used for evaluating tumor immunotherapy efficacy. The application provides a key tool for analyzing BCLAF1 phosphorylation regulation mechanism, and lays a theoretical foundation for developing an immune combined therapy strategy targeting a SIK2-BCLAF1-CCL5 axis.

The present disclosure relates to canine antibodies, binding polypeptides, scFvs specific for canine programmed death protein 1 (PD-1), nucleic acids encoding the same, and the methods to prepare the same and to use the same to treat a disease or a condition.

The invention discloses application of CREKA modified nanoparticles in treatment of retinal vascular thrombosis, and relates to the technical field of nanoparticles. The nanoparticle contains a polylactic acid-glycolic acid copolymer as a carrier and entraps a recombinant tissue type plasminogen activator and perfluoropentane, the surface of the PLGA is modified with CREKA peptide, the CREKA peptide is used for targeting thrombus fibrin, the rtPA is used for thrombolysis, and the PFP is used for phase change under the ultrasonic effect to promote drug release. According to the invention, thrombus fibrin is specifically targeted through CREKA peptide, high-efficiency enrichment of a drug at a focus part is realized, low-intensity ultrasound is combined to trigger PFP phase change blasting and promote rtPA release, the thrombolysis effect is obviously superior to that of a traditional method, in-vitro experiments show that a thrombus structure is loose after thrombolysis of a PPrC group, and change of absorbance of supernate proves that the thrombolysis rate is the highest.

The present invention relates to an antigen binding protein that specifically binds to a melanoma associated antigen (MAGE) B2 antigen peptide expressed by a tumor, which is complexed with an MHC. The antigen binding proteins are provided for use in the treatment of cancers expressing MAGEB2. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins, and pharmaceutical compositions comprising the antigen binding proteins.

This invention belongs to the field of immunoassay and discloses an antigenic peptide phosphorylated at amino acid position 433 of CRTC2, a specific antibody, and its applications. Mass spectrometry analysis reveals for the first time the role of the CRTC2 Ser433 phosphorylation site in radiotherapy resistance, indicating that the phosphorylation level of CRTC2 Ser433 can serve as an indicator for predicting the radiosensitivity of liver cancer patients. Using the CRTC2 Ser433 phosphorylated antigenic peptide: CPHHRRVPLpSPLS, a specific phosphorylated antibody (CRTC2P-Ser433 antibody) is prepared for the first time. Radiosensitivity can be predicted through immunohistochemical staining scores, demonstrating both specificity and ease of detection.

Materials and methods for identifying and using MHC molecule variants for activating self-reactive T cells in a peptide-specific manner, and their use to focus autoimmune cellular responses against diseases such as cancers and persisting viral infections, are described.